These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 177360

  • 1. Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation.
    Menezes J, Jondal M, Leibold W, Dorval G.
    Infect Immun; 1976 Feb; 13(2):303-10. PubMed ID: 177360
    [Abstract] [Full Text] [Related]

  • 2. Lymphoblastoid transformation and kinetics of appearance of viral nuclear antigen (EBNA) in cord-blood lymphocytes infected by Epstein-Barr Virus (EBV).
    Yata J, Desgranges C, Nakagawa T, Favre MC, De-The G.
    Int J Cancer; 1975 Mar 15; 15(3):377-84. PubMed ID: 49325
    [Abstract] [Full Text] [Related]

  • 3. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.
    Menezes J, Leibold W, Klein G, Clements G.
    Biomedicine; 1975 Jul 15; 22(4):276-84. PubMed ID: 179629
    [Abstract] [Full Text] [Related]

  • 4. Induction of Epstein-Barr virus-associated nuclear antigen during in vitro transformation of human lymphoid cells.
    Leibold W, Flanagan TD, Menezes J, Klein G.
    J Natl Cancer Inst; 1975 Jan 15; 54(1):65-8. PubMed ID: 163326
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA.
    Dillner J, Kallin B, Ehlin-Henriksson B, Timar L, Klein G.
    Int J Cancer; 1985 Mar 15; 35(3):359-66. PubMed ID: 2982749
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of enhancement of Epstein-Barr virus-induced transformation of peripheral blood lymphocytes by a tumor promoter, TPA, with special reference to lowering of cytotoxicity of T cells.
    Harada S, Katsuki T, Yamamoto H, Hinuma Y.
    Int J Cancer; 1981 May 15; 27(5):617-23. PubMed ID: 6270019
    [Abstract] [Full Text] [Related]

  • 7. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB, Lee SP, Haurum JS, Murray N, Yao QY, Rowe M, Signoret N, Rickinson AB, McMichael AJ.
    J Exp Med; 1995 Jun 01; 181(6):2221-8. PubMed ID: 7539044
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
    Sharif-Askari E, Fawaz LM, Tran P, Ahmad A, Menezes J.
    J Natl Cancer Inst; 2001 Nov 21; 93(22):1724-32. PubMed ID: 11717333
    [Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus susceptibility of normal human B lymphocyte populations.
    Aman P, Ehlin-Henriksson B, Klein G.
    J Exp Med; 1984 Jan 01; 159(1):208-20. PubMed ID: 6319530
    [Abstract] [Full Text] [Related]

  • 12. Mitotic EBNA-positive lymphocytes in peripheral blood during infectious mononucleosis.
    Robinson J, Smith D, Niederman J.
    Nature; 1980 Sep 25; 287(5780):334-5. PubMed ID: 6252472
    [Abstract] [Full Text] [Related]

  • 13. Analysis of the transformation of human lymphocytes by Epstein-Barr virus III. Induction of early events by P3HR-1 strain without subsequent immortalization.
    Takada K, Osato T.
    Med Microbiol Immunol; 1981 Sep 25; 170(1):19-26. PubMed ID: 6272076
    [Abstract] [Full Text] [Related]

  • 14. Infection of mouse lymphocytes by Epstein-Barr virus. II. Stimulation of cellular DNA synthesis by EBV in the absence of EBNA induction and cell transformation.
    Gross TG, Volsky DJ.
    Virology; 1984 Feb 25; 133(1):211-5. PubMed ID: 6322431
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro.
    Cohen JI, Picchio GR, Mosier DE.
    J Virol; 1992 Dec 25; 66(12):7555-9. PubMed ID: 1331538
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E.
    J Virol; 1990 May 25; 64(5):2309-18. PubMed ID: 2157887
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic effector cells from infectious mononucleosis patients in the acute phase do not specifically kill Epstein-Barr virus genome-carrying lymphoid cell lines.
    Patel PC, Dorval G, Menezes J.
    Infect Immun; 1982 Oct 25; 38(1):251-9. PubMed ID: 6292093
    [Abstract] [Full Text] [Related]

  • 18. [Analysis of Epstein-Barr virus transformation of human lymphocytes: susceptibility of B lymphocyte subpopulations and differentiation stage of the transformed cells].
    Koizumi S.
    Hokkaido Igaku Zasshi; 1985 Sep 25; 60(5):724-34. PubMed ID: 3000906
    [Abstract] [Full Text] [Related]

  • 19. Primary EBV infection of human umbilical cord lymphocytes and EBV genome-negative lymphoblastoid cell lines (BJAB and Ramos).
    Takimoto T, Sato H, Ogura H.
    Auris Nasus Larynx; 1986 Sep 25; 13(3):199-205. PubMed ID: 3036055
    [Abstract] [Full Text] [Related]

  • 20. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB.
    J Exp Med; 1992 Jul 01; 176(1):157-68. PubMed ID: 1319456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.